Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Brienza

Showing results (41-50 of 55) with videos related to

Pageof 6
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 1996
Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil, and leucovorin in patients with metastatic colorectal cancerF Bertheault-Cvitkovic, A Jami, M Ithzaki, et al.
European Journal of Cancer (Oxford, England : 1990)|December 16, 1998
Phase II study of oxaliplatin in poor-prognosis non-small cell lung cancer (NSCLC). ATTIT. Association pour le Traitement des Tumeurs Intra ThoraciquesI Monnet, S Brienza, F Hugret, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 4, 1999
Preliminary results on the activity of oxaliplatin (L-OHP) in refractory/recurrent non-Hodgkin's lymphoma patientsN Germann, S Brienza, M Rotarski, et al.
Anti-Cancer Drugs|June 13, 1998
Determination of unbound platinum after oxaliplatin administration: comparison of currently available methods and influence of various parametersE Gamelin, M Boisdron-Celle, A Lebouil, et al.
Cancer|February 15, 1992
A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancerF Lévi, J L Misset, S Brienza, et al.
Cancer|June 22, 1999
A multicenter evaluation of intensified, ambulatory, chronomodulated chemotherapy with oxaliplatin, 5-fluorouracil, and leucovorin as initial treatment of patients with metastatic colorectal carcinoma. International Organization for Cancer ChronotherapyF Lévi, R Zidani, S Brienza, et al.
European Journal of Cancer (Oxford, England : 1990)|November 30, 2000
Factors predicting for efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU)+/-folinic acid (FA) in a compassionate-use cohort of 370 5-FU-resistant advanced colorectal cancer (CRC) patientsBensmaïne, A de Gramont, S Brienza, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 13, 2001
Use of the ratio of time to progression following first- and second-line therapy to document the activity of the combination of oxaliplatin with 5-fluorouracil in the treatment of colorectal carcinomaA Bonetti, M Zaninelli, R Leone, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 1, 1997
Cumulative pharmacokinetic study of oxaliplatin, administered every three weeks, combined with 5-fluorouracil in colorectal cancer patientsE Gamelin, A L Bouil, M Boisdron-Celle, et al.
Anti-Cancer Drugs|September 23, 2000
Overcoming resistance to chronomodulated 5-fluorouracil and folinic acid by the addition of chronomodulated oxaliplatin in advanced colorectal cancer patientsC Garufi, S Brienza, P Pugliese, et al.
Pageof 6

Showing results (41-50 of 55) with videos related to

Sort By:
Pageof 6
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 1996
Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil, and leucovorin in patients with metastatic colorectal cancerF Bertheault-Cvitkovic, A Jami, M Ithzaki, et al.
European Journal of Cancer (Oxford, England : 1990)|December 16, 1998
Phase II study of oxaliplatin in poor-prognosis non-small cell lung cancer (NSCLC). ATTIT. Association pour le Traitement des Tumeurs Intra ThoraciquesI Monnet, S Brienza, F Hugret, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 4, 1999
Preliminary results on the activity of oxaliplatin (L-OHP) in refractory/recurrent non-Hodgkin's lymphoma patientsN Germann, S Brienza, M Rotarski, et al.
Anti-Cancer Drugs|June 13, 1998
Determination of unbound platinum after oxaliplatin administration: comparison of currently available methods and influence of various parametersE Gamelin, M Boisdron-Celle, A Lebouil, et al.
Cancer|February 15, 1992
A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancerF Lévi, J L Misset, S Brienza, et al.
Cancer|June 22, 1999
A multicenter evaluation of intensified, ambulatory, chronomodulated chemotherapy with oxaliplatin, 5-fluorouracil, and leucovorin as initial treatment of patients with metastatic colorectal carcinoma. International Organization for Cancer ChronotherapyF Lévi, R Zidani, S Brienza, et al.
European Journal of Cancer (Oxford, England : 1990)|November 30, 2000
Factors predicting for efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU)+/-folinic acid (FA) in a compassionate-use cohort of 370 5-FU-resistant advanced colorectal cancer (CRC) patientsBensmaïne, A de Gramont, S Brienza, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 13, 2001
Use of the ratio of time to progression following first- and second-line therapy to document the activity of the combination of oxaliplatin with 5-fluorouracil in the treatment of colorectal carcinomaA Bonetti, M Zaninelli, R Leone, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 1, 1997
Cumulative pharmacokinetic study of oxaliplatin, administered every three weeks, combined with 5-fluorouracil in colorectal cancer patientsE Gamelin, A L Bouil, M Boisdron-Celle, et al.
Anti-Cancer Drugs|September 23, 2000
Overcoming resistance to chronomodulated 5-fluorouracil and folinic acid by the addition of chronomodulated oxaliplatin in advanced colorectal cancer patientsC Garufi, S Brienza, P Pugliese, et al.
Pageof 6